Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

826 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
Qualls DA, Lambert N, Caimi PF, Merrill M, Pullarkat P, Godby RC, Bond DA, Wehmeyer GT, Romancik J, Amoozgar B, Leslie L, Nastoupil LJ, Crombie JL, Abramson JS, Khurana A, Nowakowski GS, Maddocks K, Rutherford SC, Kahl B, Okwali M, Buege MJ, Seshan V, Batlevi CL, Salles G. Qualls DA, et al. Among authors: khurana a. Blood. 2023 Dec 28;142(26):2327-2331. doi: 10.1182/blood.2023021274. Blood. 2023. PMID: 37738563
Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study.
Tun AM, Khurana A, Mwangi R, Link BK, Wang Y, Feldman AL, Thompson CA, Novak AJ, Villasboas JC, Thanarajasingam G, Farooq U, Syrbu S, Nowakowski GS, Witzig TE, Ansell SM, Rimsza LM, Cerhan JR, Habermann TM, Maurer MJ. Tun AM, et al. Among authors: khurana a. Blood Adv. 2022 Sep 13;6(17):5210-5221. doi: 10.1182/bloodadvances.2022007990. Blood Adv. 2022. PMID: 35849723 Free PMC article.
Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy.
Bezerra ED, Iqbal M, Munoz J, Khurana A, Wang Y, Maurer MJ, Bansal R, Hathcock MA, Bennani N, Murthy HS, Rosenthal AC, Paludo J, Villasboas JC, Johnston PB, Habermann TM, Ansell SM, Castro JE, Witzig TE, Kharfan-Dabaja MA, Nowakowski GS, Lin Y. Bezerra ED, et al. Among authors: khurana a. Blood Adv. 2023 Apr 25;7(8):1572-1576. doi: 10.1182/bloodadvances.2022007868. Blood Adv. 2023. PMID: 36219588 Free PMC article. No abstract available.
High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course.
O'Donoghue DF, Truong HL, Finnes HD, McDonald JS, May HP, Ansell SM, Bennani NN, Habermann TM, Inwards DJ, Johnston PB, Khurana A, Lin Y, Micallef IN, Nowakowski GS, Paludo J, Porrata LF, Thanarajasingam G, Thompson CA, Villasboas JC, Wang Y, Witzig TE, Leung N. O'Donoghue DF, et al. Among authors: khurana a. JCO Oncol Pract. 2022 Dec;18(12):e1908-e1917. doi: 10.1200/OP.22.00182. Epub 2022 Oct 14. JCO Oncol Pract. 2022. PMID: 36240468
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.
Steiner RE, Hwang SR, Khurana A, Habermann TM, Epperla N, Annunzio K, Allen PB, Baird K, Paulino D, Alderuccio JP, Lossos IS, David K, Evens AM, Pandya K, Bair SM, Kamdar M, Ba Aqeel S, Torka P, Lynch R, Smith S, Feng L, Noorani M, Ahmed S, Nair R, Vega F, Wu S, Fang P, Pinnix CC, Gunther JR, Dabaja BS, Lee HJ. Steiner RE, et al. Among authors: khurana a. Blood Adv. 2023 Dec 26;7(24):7485-7493. doi: 10.1182/bloodadvances.2023010700. Blood Adv. 2023. PMID: 37603594 Free PMC article.
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.
Rezazadeh A, Szabo A, Khurana A, Inwards DJ, Lunning MA, Bartlett NL, Caimi PF, Rodgers TD, Barr PM, Chowdhury SM, Epperla N, Mendries H, Hill BT, Oh TS, Karmali R, Chang JE, Goyal G, Parsons BM, Isaac KM, Portell CA, Monahan K, Siker M, King DM, Fenske TS. Rezazadeh A, et al. Among authors: khurana a. Haematologica. 2024 May 1;109(5):1439-1444. doi: 10.3324/haematol.2023.283210. Haematologica. 2024. PMID: 37855051 Free PMC article.
Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.
Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang H, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC. Locke FL, et al. Among authors: khurana a. Blood. 2024 Apr 18:blood.2023023447. doi: 10.1182/blood.2023023447. Online ahead of print. Blood. 2024. PMID: 38635762
826 results